在BRAF抑制剂的目标之外,会破坏内皮信号传递和血管屏障功能
Sophie Bromberger1, Yuliia Zadorozhna1, Julia Maria Ressler1
1Department of Dermatology, Medical University of Vienna, Vienna, Austria.
Life science alliance
|June 5, 2024
概括
用于黑色素瘤的BRAF抑制剂可以悖论地激活血管细胞中的MAPK信号,导致某些药物但不是其他药物的障碍功能受损. 这揭示了BRAF抑制剂明显的内皮副作用.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 结合BRAF抑制剂 (BRAFi) 和MEK抑制剂 (MEKi) 的向疗法是晚期黑色素瘤的标准.
- 治疗疗效受到药物耐药性和不良事件 (AE) 的限制,可能与BRAFi目标乱交有关.
- BRAFi对血管内皮的影响,该内皮会遇到高度的药物,仍然在很大程度上是未知的.
研究的目的:
- 为了研究临床批准的BRAFi对血管内皮细胞的影响.
- 描述对BRAFi治疗的内皮反应,包括信号通路激活和功能变化.
主要方法:
- 用经批准的BRAFi (vemurafenib,dabrafenib,encorafenib) 和下一代抑制剂 (PLX8394) 治疗内皮细胞.
- 对内皮MAPK信号通路激活的分析.
- 蛋白质定型以确定非目标相互作用.
- 评估内皮质屏障功能和结合完整性.
主要成果:
- 临床批准的BRAFi诱导了内皮MAPK信号的矛盾激活.
- 每个BRAFi通过基蛋白质组学识别出不同的非标蛋白组.
- 维穆拉菲尼布和PLX8394损害了内皮屏障功能和结合完整性.
- 达布拉费尼布和恩科拉费尼布没有显著影响内皮屏障功能.
结论:
- BRAFi对血管内皮表现出明显的非目标效应,以不同的方式影响信号和屏障功能.
- 了解这些内皮细胞特异性影响对于阐明黑色素瘤患者的副作用机制至关重要.
- 这些发现可以指导开发更安全,更有效的BRAF向疗法.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Intracellular Signaling Affects Focal Adhesions
2.7K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
153
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
Mechanism of Angiogenesis
5.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.4K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K


